Next-generation HIV integrase inhibitors (ALLINI)
Structural and Chemical Analysis of Highly Potent ALLINI Platform
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11330295
Developing new HIV medicines that work differently to help people living with HIV who face drug resistance or side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11330295 on ClinicalTrials.gov |
What this research studies
This project focuses on a new class of HIV drugs called ALLINIs that target the virus's integrase protein at a non-traditional site. Researchers will study the chemical structures and how these compounds bind the viral protein using lab tests, cell models, and animal studies. The aim is to design molecules that disrupt virus maturation, raise the barrier to resistance, improve safety, and enable long-acting dosing. This work is primarily laboratory and preclinical and does not currently involve treating people.
Who could benefit from this research
Good fit: While this grant is preclinical, the eventual clinical candidates would be people living with HIV who have resistance to current integrase inhibitors or who need long-acting treatment options.
Not a fit: People without HIV or those who are stable and well-controlled on existing antiretroviral therapy are unlikely to see direct benefit in the near term.
Why it matters
Potential benefit: Could lead to HIV therapies that stay effective against resistant virus strains, have fewer side effects, and possibly require less frequent dosing.
How similar studies have performed: Related ALLINI compounds have shown promising results in laboratory and animal experiments, but none have yet reached approved human treatments.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, BAEK — EMORY UNIVERSITY
- Study coordinator: KIM, BAEK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.